Aratana Therapeutics, Inc. (NASDAQ:PETX) – Equities research analysts at William Blair dropped their FY2020 earnings estimates for shares of Aratana Therapeutics in a report issued on Monday. William Blair analyst J. Kreger now expects that the biopharmaceutical company will post earnings per share of $0.83 for the year, down from their prior estimate of $0.90.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 52.00%. The company had revenue of $5.16 million during the quarter, compared to the consensus estimate of $4.50 million. During the same period last year, the firm earned $0.61 EPS. The company’s revenue for the quarter was down 86.4% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: “Aratana Therapeutics, Inc. (NASDAQ:PETX) to Post FY2020 Earnings of $0.83 Per Share, William Blair Forecasts” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/aratana-therapeutics-inc-nasdaqpetx-to-post-fy2020-earnings-of-0-83-per-share-william-blair-forecasts.html.

Several other brokerages have also recently weighed in on PETX. BidaskClub cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Zacks Investment Research cut Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Aratana Therapeutics in a research note on Sunday, May 14th. Finally, Stifel Nicolaus reduced their price target on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Aratana Therapeutics (PETX) traded down 2.40% during midday trading on Tuesday, hitting $6.11. 191,120 shares of the stock were exchanged. The firm’s 50-day moving average is $7.07 and its 200 day moving average is $6.46. Aratana Therapeutics has a 52 week low of $4.97 and a 52 week high of $10.73. The stock’s market cap is $231.92 million.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Aratana Therapeutics by 13.9% in the first quarter. Vanguard Group Inc. now owns 1,926,554 shares of the biopharmaceutical company’s stock worth $10,211,000 after buying an additional 235,208 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Aratana Therapeutics by 281.4% in the first quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock worth $1,464,000 after buying an additional 203,738 shares in the last quarter. General American Investors Co. Inc. boosted its stake in Aratana Therapeutics by 18.0% in the second quarter. General American Investors Co. Inc. now owns 618,660 shares of the biopharmaceutical company’s stock worth $4,473,000 after buying an additional 94,201 shares in the last quarter. Tocqueville Asset Management L.P. boosted its stake in Aratana Therapeutics by 56.3% in the first quarter. Tocqueville Asset Management L.P. now owns 250,000 shares of the biopharmaceutical company’s stock worth $1,325,000 after buying an additional 90,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Aratana Therapeutics by 85.7% in the first quarter. Dimensional Fund Advisors LP now owns 128,240 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 59,181 shares in the last quarter. 67.85% of the stock is currently owned by hedge funds and other institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.